AXSM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Axsome Therapeutics Inc (AXSM) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows strong growth potential driven by its flagship drug Auvelity, positive analyst sentiment, and upcoming catalysts like the Alzheimer's disease agitation indication launch. Technical indicators are bullish, and options sentiment leans positive, supporting a buy decision.
The stock is in a bullish trend with SMA_5 > SMA_20 > SMA_200, MACD histogram above 0, and RSI_6 at 63.853 in the neutral zone. Key support is at 233.15, and resistance levels are at 257.56 and 265.1. The stock is well-positioned for further upside.
Analysts have raised price targets significantly, with the highest target at $310, citing strong sales growth for Auvelity and its potential in Alzheimer's disease agitation.
Axsome's participation in Alzheimer's awareness campaigns and its strong Q1 sales growth (+59%) highlight its commitment to its pipeline and market expansion.
Bullish technical indicators and a strong support level at 233.15.
Regular market price change shows a slight decline of -0.66%, indicating short-term volatility.
No recent significant hedge fund or insider trading activity, which could indicate a lack of major institutional moves.
The company reported a 59% increase in Q1 sales for its Auvelity drug, indicating strong growth momentum. However, detailed financial data is unavailable for deeper analysis.
Analysts are overwhelmingly positive on AXSM, with multiple firms raising price targets and maintaining Buy or Outperform ratings. The consensus highlights confidence in Auvelity's growth potential and the upcoming Alzheimer's disease agitation indication launch.
